CRISPR gene screening system:looking for affect cancer cell survival conditions

introduction: Cold Spring Harbor laboratory CSHL’s Professor Christopher Vakoc, PhD and colleagues report, by blocking the LKB1 or salt-induced kinase, it can block the MEF2C-driven AML cell growth. Vakoc said, these enzymes interfere with the ability of the small molecule compound is a potential drug development target. Game industry xiaobian for you recommend a“CRISPR gene filtering system: look for the affect cancer cell survival conditions”, as follows:

MEF2C is a transcription factor, about 15% of acute myeloid leukemia（AML）cases are associated with MEF2C over-activation. Curb MEF2C, will most likely relieve the AML condition.

CSHL Associate Professor Christopher Vakoc, PhD and colleagues report, by blocking the LKB1 or salt-induced kinase, it can block the MEF2C-driven AML cell growth. Vakoc said, these enzymes interfere with the ability of the small molecule compound is a potential drug development target.

In order to develop AML treatment strategies, in early 2013, Vakoc team designed a based on CRISPR genome editing tools for large-scale gene screening system, to find the impact cancer cell survival conditions.

in the Vakoc lab a Bo after the researcher Yusuke Tarumoto, under the leadership of screening results is finally beginning to bear fruit. They found that LKB1 and salt-induced kinase is a specific type of AML growth must be conditions, previously, these two enzymes have not been identified with AML the presence of Association. Through further experiments, the researchers also Savas discovery of a known cancer gene promoter MEF2C, to sort out this article about cancer survival in new ways.

“at the end of the project, I realized that we actually found a way to manipulate the transcription factors of the effective methods,”Vakoc excitedly said.“ Most of the leukemia by the transcription factors out of control cause, and therefore, this protein is considered to be the most challenging drug targets.”

although, under laboratory conditions the use of closed LKB1 and salt-inducible kinase of the chemicals does not apply to clinical treatment, but Vakoc optimistic showing, for a target point of the drug is not difficult to design, at present, they have started to conduct animal model tests.

The original retrieval: LKB1, Salt-Inducible Kinases, and MEF2C are linked dependencies in acute myeloid leukemia. Molecular Cell

this article from the biological flux, reprint aims to share the insights. If infringement, please inform to remove!< a href="https://www.sohu.com/?strategyid=00001" target="_blank" title="click to enter Sohu home" id="backsohucom">return to Sohu, view more

editor: